Skip to main content

Warning notification:Warning

Unfortunately, you are using an outdated browser. Please, upgrade your browser to improve your experience with HSE. The list of supported browsers:

  1. Chrome
  2. Edge
  3. FireFox
  4. Opera
  5. Safari
HSE National Clinical Guideline

National Clinical Guideline: Antenatal Corticosteroids to Reduce Neonatal Morbidity and Mortality


Topic: Antenatal corticosteroids to reduce neonatal morbidity and mortality
Document Owner: National Clinical Lead for Guideline Development in Maternity and Gynaecology Services, National Women and Infants Health Programme (NWIHP)
National Group: Guideline Development Programme, National Women and Infants Health Programme
Effective From: 31/05/2024
This Guideline aims to provide evidence-based recommendations for the administration of antenatal corticosteroids, over a variety of pre-defined gestational ranges and clinical circumstances.
National Clinical Guideline: Antenatal Corticosteroids to Reduce Neonatal Morbidity and Mortality
PDF, 2.44MB

This National Clinical Practice Guideline provides an evidence-based framework for antenatal corticosteroid administration to reduce neonatal morbidity and mortality.

It specifies indications, gestational-age thresholds, dosage regimens and timing where preterm birth is anticipated, including at the threshold of viability.

It also addresses late-preterm and term caesarean birth, multiple pregnancy, diabetes, preterm prelabour rupture of membranes, infection and repeat courses, emphasising individualised counselling and the balance between neonatal benefit and potential maternal or neonatal harms.

Back to HSE National Central Repository